| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Kunitoshi Kamijima, Mayumi Aok. Effectiveness of paroxetine in the treatment of obsessive-compulsive disorders. Expert review of neurotherapeutics. vol 6. issue 7. 2006-08-09. PMID:16831110. |
among six different selective serotonin reuptake inhibitors (paroxetine, sertraline, fluoxetine, fluvoxamine, citalopram, escitalopram) that are available worldwide, paroxetine has the broadest treatment spectrum and promises great benefits not only for obsessive-compulsive disorder patients, but also for those with comorbid depression and/or various kinds of anxiety disorders. |
2006-08-09 |
2023-08-12 |
Not clear |
| Wendy Chrapko, Paul Jurasz, Marek W Radomski, Stephen L Archer, Stephen C Newman, Glen Baker, Nathalie Lara, Jean-Michel Le Melléd. Alteration of decreased plasma NO metabolites and platelet NO synthase activity by paroxetine in depressed patients. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 31. issue 6. 2006-08-07. PMID:16319917. |
the purpose of this paper is to further investigate a potential mechanism involving nitric oxide (no) and to examine the effect of the selective serotonin reuptake inhibitor paroxetine on no production by both platelets and the endothelium. |
2006-08-07 |
2023-08-12 |
human |
| T M du Bois, C Deng, W Bell, X-F Huan. Fatty acids differentially affect serotonin receptor and transporter binding in the rat brain. Neuroscience. vol 139. issue 4. 2006-07-26. PMID:16600514. |
using beta-imager quantification techniques, [(3)h]ketanserin, [(3)h]mesulergine and [(3)h]paroxetine binding to serotonin (5-ht)(2a), 5-ht(2c) receptors and 5-ht transporters (5-htt) was measured throughout the brain in all four groups. |
2006-07-26 |
2023-08-12 |
rat |
| David S Baldwin, Claire Polkinghor. Evidence-based pharmacotherapy of Generalized Anxiety Disorder. The international journal of neuropsychopharmacology. vol 8. issue 2. 2006-07-19. PMID:15576000. |
due to their efficacy in gad and comorbid anxiety and depressive disorders, their tolerability and safety, certain selective serotonin re-uptake inhibitors (escitalopram, paroxetine, sertraline) should be considered the first-line treatment for most patients, although the serotonin-noradrenaline re-uptake inhibitor venlafaxine is a reasonable alternative. |
2006-07-19 |
2023-08-12 |
Not clear |
| Terje Vasskog, Urs Berger, Per-Jostein Samuelsen, Roland Kallenborn, Einar Jense. Selective serotonin reuptake inhibitors in sewage influents and effluents from Tromsø, Norway. Journal of chromatography. A. vol 1115. issue 1-2. 2006-07-19. PMID:16574138. |
an analytical method for quantification of the selective serotonin reuptake inhibitors (ssris) citalopram, sertraline, paroxetine, fluoxetine and fluvoxamine in sewage influents and effluents from selected sewage treatment plants (stps) has been developed and validated. |
2006-07-19 |
2023-08-12 |
Not clear |
| Zsuzsa Aszaló. [Effects of antidepressants on sleep]. Orvosi hetilap. vol 147. issue 17. 2006-07-14. PMID:16780185. |
selective serotonin reuptake inhibitors, except paroxetine, improve sleep only at the time and to the extent of restoring depression. |
2006-07-14 |
2023-08-12 |
Not clear |
| Tomoko Ishii, Takayasu Ohtake, Takeo Yasu, Yasuhiro Kadotani, Shuji Hayashi, Machiko Oka, Kyoko Maesato, Tsutomu Mano, Ryota Ikee, Hidekazu Moriya, Shuzo Kobayash. A rare case of combined syndrome of inappropriate antidiuretic hormone secretion and Fanconi syndrome in an elderly woman. American journal of kidney diseases : the official journal of the National Kidney Foundation. vol 48. issue 1. 2006-07-07. PMID:16797399. |
the cause was thought to be the antidepressant paroxetine, which is a selective serotonin reuptake inhibitor (ssri). |
2006-07-07 |
2023-08-12 |
Not clear |
| Elaine M Jagoda, Lixin Lang, Joji Tokugawa, Ashlie Simmons, Ying Ma, Carlo Contoreggi, Dale Kiesewetter, William C Eckelma. Development of 5-HT1A receptor radioligands to determine receptor density and changes in endogenous 5-HT. Synapse (New York, N.Y.). vol 59. issue 6. 2006-06-28. PMID:16440292. |
the 5-ht(1a)r selectivity of [(18)f]fpway was confirmed using ex vivo autoradiography studies with 5-ht(1a)r knockout, heterozygous, and wildtype mice.pre- or post-treatment of awake rodents in tissue dissection studies with paroxetine had no effect on hippocampal binding of [(18)f]fcway or [(18)f]fpway compared to controls, indicating neither tracer was sensitive to changes in endogenous 5-ht. |
2006-06-28 |
2023-08-12 |
mouse |
| K Shinomiya, Y Fujii, Y Sugimoto, N Azuma, S Tokunaga, K Kitazumi, C Kame. Effect of paroxetine on marble-burying behavior in mice. Methods and findings in experimental and clinical pharmacology. vol 27. issue 10. 2006-06-15. PMID:16395417. |
the present study was undertaken to investigate the effect of paroxetine, a selective serotonin reuptake inhibitor (ssri), on marble-burying behavior in mice in comparison with those of fluvoxamine and clomipramine. |
2006-06-15 |
2023-08-12 |
mouse |
| Deidre B Clark, Miranda R Andrus, Debbie C Byr. Drug interactions between linezolid and selective serotonin reuptake inhibitors: case report involving sertraline and review of the literature. Pharmacotherapy. vol 26. issue 2. 2006-06-14. PMID:16466332. |
several cases of serotonin syndrome in patients taking linezolid and ssris have been reported, including two reports with sertraline, one with paroxetine, four with citalopram, and two with fluoxetine. |
2006-06-14 |
2023-08-12 |
Not clear |
| Deidre B Clark, Miranda R Andrus, Debbie C Byr. Drug interactions between linezolid and selective serotonin reuptake inhibitors: case report involving sertraline and review of the literature. Pharmacotherapy. vol 26. issue 2. 2006-06-14. PMID:16466332. |
one abstract of a retrospective analysis reported that serotonin syndrome did not occur in patients who received linezolid and fluoxetine, paroxetine, or sertraline. |
2006-06-14 |
2023-08-12 |
Not clear |
| Bernardo Dell'Osso, Andrea Allen, Eric Hollande. Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder. Expert opinion on pharmacotherapy. vol 6. issue 15. 2006-06-12. PMID:16316311. |
in the last two decades, the anti-obsessional effect of fluvoxamine has been tested in several double-blind, placebo-controlled and active-comparison studies, demonstrating its superior efficacy over obsessions and compulsions compared with non-serotonergic antidepressants (i.e., desipramine) and equal efficacy to clomipramine (a tricyclic antidepressant with potent serotonin re-uptake inhibition) and other selective serotonin re-uptake inhibitors (paroxetine and citalopram). |
2006-06-12 |
2023-08-12 |
Not clear |
| David S Baldwin, Rajesh V Nai. Escitalopram in the treatment of generalized anxiety disorder. Expert review of neurotherapeutics. vol 5. issue 4. 2006-06-05. PMID:16026227. |
in summary, escitalopram is effective and well tolerated in both the short- and long-term treatment of generalized anxiety disorder, and has advantages over benzodiazepines and the selective serotonin reuptake inhibitor paroxetine. |
2006-06-05 |
2023-08-12 |
Not clear |
| P M Haddad, B R Pal, P Clarke, A Wieck, S Sridhira. Neonatal symptoms following maternal paroxetine treatment: serotonin toxicity or paroxetine discontinuation syndrome? Journal of psychopharmacology (Oxford, England). vol 19. issue 5. 2006-05-30. PMID:16166193. |
neonatal symptoms following maternal paroxetine treatment: serotonin toxicity or paroxetine discontinuation syndrome? |
2006-05-30 |
2023-08-12 |
Not clear |
| P M Haddad, B R Pal, P Clarke, A Wieck, S Sridhira. Neonatal symptoms following maternal paroxetine treatment: serotonin toxicity or paroxetine discontinuation syndrome? Journal of psychopharmacology (Oxford, England). vol 19. issue 5. 2006-05-30. PMID:16166193. |
serotonin toxicity due to paroxetine seems the most likely mechanism, though an important differential diagnosis is a paroxetine discontinuation (withdrawal) syndrome. |
2006-05-30 |
2023-08-12 |
Not clear |
| Nicolas Aznavour, Latifa Rbah, Lucienne Léger, Colette Buda, Jean-Pierre Sastre, Anouk Imhof, Yves Charnay, Luc Zimme. A comparison of in vivo and in vitro neuroimaging of 5-HT 1A receptor binding sites in the cat brain. Journal of chemical neuroanatomy. vol 31. issue 3. 2006-05-26. PMID:16517120. |
to validate the cat as a suitable model for positron emission tomography imaging (pet) and to gain further knowledge on the anatomical distribution of the serotonin-1a receptor (5-ht 1a) in the feline brain, we used pet with [18f]mppf and in vitro autoradiography with [3h]mppf, [3h]8-oh-dpat and [3h]paroxetine. |
2006-05-26 |
2023-08-12 |
cat |
| Michihiko Iijima, Shigeyuki Chak. Separation-induced ultrasonic vocalization in rat pups: further pharmacological characterization. Pharmacology, biochemistry, and behavior. vol 82. issue 4. 2006-05-09. PMID:16359723. |
furthermore, as with selective serotonin reuptake inhibitors such as fluvoxamine and paroxetine, siv was also reduced by the serotonin and noradrenaline reuptake inhibitor milnacipran and the metabotropic glutamate receptor 5 antagonist mpep, while desipramine was without effect. |
2006-05-09 |
2023-08-12 |
rat |
| Miki Yamauchi, Takako Miyara, Tetsuya Matsushima, Taiichiro Imanish. Desensitization of 5-HT2A receptor function by chronic administration of selective serotonin reuptake inhibitors. Brain research. vol 1067. issue 1. 2006-05-02. PMID:16360124. |
we have previously shown that chronic treatment with selective serotonin reuptake inhibitors (ssris), fluvoxamine and paroxetine, attenuated m-chlorophenylpiperazine (mcpp)-induced hypolocomotion in rats. |
2006-05-02 |
2023-08-12 |
rat |
| Miki Yamauchi, Takako Miyara, Tetsuya Matsushima, Taiichiro Imanish. Desensitization of 5-HT2A receptor function by chronic administration of selective serotonin reuptake inhibitors. Brain research. vol 1067. issue 1. 2006-05-02. PMID:16360124. |
these results suggest that the desensitization of 5-ht2a receptor function occurs in the same way as that of 5-ht2c receptor function through chronic treatment with either fluvoxamine or paroxetine as a consequence of prolonged exposure to elevated levels of serotonin. |
2006-05-02 |
2023-08-12 |
rat |
| Pinhas N Dannon, Katherine Lowengrub, I Iancu, Moshe Kotle. Paroxetine in panic disorder: clinical management and long-term follow-up. Expert review of neurotherapeutics. vol 4. issue 2. 2006-04-25. PMID:15853560. |
paroxetine is unique among the selective serotonin reuptake inhibitors since, in addition to its effect on the cns serotonergic neurotransmission, it also has mild noradrenergic properties demonstrated to be effective in the treatment of anxiety disorders and depression. |
2006-04-25 |
2023-08-12 |
Not clear |